Thrombotic complications are frequent in COVID‐19 and contribute significantly to mortality
and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be …

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The …

Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality.
The technological landscape for management of acute intermediate-and high-risk PE is …

Background The identification of hemodynamically stable pulmonary embolism (PE) patients
who may benefit from advanced treatment beyond anticoagulation is unclear. However …

For patients with venous thromboembolism (VTE), prediction of bleeding is relevant
throughout the course of treatment, although the means and goal of this prediction differ …

Pulmonary embolism (PE) presents a spectrum of hemodynamic consequences, ranging
from being asymptomatic to a life-threatening medical emergency. Management of …

Background Improved prediction of the risk of major bleeding in patients with acute
pulmonary embolism (PE) receiving systemic thrombolysis is crucial to guide the choice of …

To compare the efficacy and safety of systemic and catheter directed thrombolysis for
patients with pulmonary embolism. Pubmed and Cochrane Central Register of Controlled …

Acute pulmonary embolism (PE) is associated with significant morbidity and mortality. The
management paradigm for acute PE has evolved in recent years with wider availability of …

Approximately 5% of pulmonary embolism (PE) cases present with persistent hypotension,
obstructive shock, or cardiac arrest. Given the high short-term mortality, management of high …